12:00 AM
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

MACI regulatory update

Sanofi disclosed in its 2Q13 earnings that in June it received marketing approval in the EU for its MACI matrix-induced autologous chrondrocyte implant for the repair of symptomatic, full-thickness cartilage defects of the...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >